Telehealth and personalised medicine company InTelelabs Inc said on Tuesday that its elicity proprietary telehealth plaform is now offering the first COVID-19 antibody test that allows patients to collect dried blood spot samples at home.
elicity's first COVID-19 antibody test has received US FDA Emergency Use Authorization (EUA) for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorisation is revoked sooner.
Available through a collaboration with Symbiotica Inc, elicity's COVID-19 Self-Collected Antibody Test System is authorised for prescription use with a fingerstick dried blood sample that is self-collected by an individual age 18 years or older, or collected by an adult from an individual five years of age and older.
It is still unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The company's test aids in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results